Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Zirconium 89 5B1 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Diagnostic use; First in man; Pharmacokinetics
- Sponsors MabVax Therapeutics
- 14 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.
- 14 Mar 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.
- 07 Sep 2017 According to a MabVax Therapeutics media release, data will be presented at the 19th Annual Rodman & Renshaw Global Investment Conference.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History